- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02334098
Omega-3 Supplementation and Behavior Problems
Omega-3 Supplementation and Behavior Problems in Children and Adolescents
The objectives of this project are as follows:
- To assess whether omega-3 dietary supplementation for six months can reduce externalizing behavior problems (antisocial and aggressive behavior) in schoolchildren aged 8 to 18, both at the end of treatment and six months post-treatment
- To assess whether omega-3 supplementation is more effective in children with more psychopathic-like traits.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Externalizing behavior problems (aggressive and antisocial behaviors) are widely recognized as predisposing to significant mental health problems and violence among adolescents in secondary schools. These in turn result in enormous economic and social costs to schools as well as to society. These costs include mental illness, crime, and violence. Similarly, violence is widely recognized as a major public health problem which has also largely defied successful intervention and prevention. Because an increasing body of research is documenting health and neurobiological risk factors for aggression and violence, part of this prevention failure may be due to intervention efforts ignoring biological contributory factors which include impaired neurocognitive and psychophysiological functioning. One benign biological intervention that may help attenuate behavior problems in children consists of omega-3 supplementation of the diet, a long-chain fatty acid critical for brain structure and function.
The overarching aim of this study is to assess whether omega-3 supplementation can reduce the base level of externalizing behavior problems in children and adolescents. A secondary but important aim is to assess whether any behavioral improvement may be greater in more psychopathic children. The specific aims are as follows:
- To assess the effectiveness of omega-3 dietary supplementation in reducing externalizing behaviors in adolescents.
- To assess whether omega-3 supplementation leads to greater improvement in children with psychopathic-like traits.
Hypotheses will be tested in a placebo-controlled, double-blind, randomized trial involving 8 to18 year-old adolescents drawn from primary and secondary schools in Hong Kong. Omega-3 supplementation will be in the form of a Norwegian fruit juice drink. 300 adolescents will be randomly assigned into: (1) omega-3 supplemented drink, (2) placebo drink, (3) treatment-as-usual controls. Behavioral measures will be assessed at baseline (0 months), end of treatment (6 months), and 6 months post-treatment (12 months).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hong Kong, China
- City University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- children and adolescents between the age 8 and 18
- participants who does not fit in any of the following exclusion criteria
Exclusion Criteria:
- unwilling to participate in a randomized, double-blind, placebo controlled trial,
- unable to give written, informed parental consent and assent from children,
- on medication that may modify lipid metabolism in the past 3 months
- significant use of omega-3 supplements in the past 6 months
- seafood allergies
- mental retardation
- epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Omega-3 supplemented drink
A 200 ml.
drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
|
The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day. 1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment. |
|
Placebo Comparator: Placebo Drink
exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
|
Treatment duration is 6 months.
They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
|
|
No Intervention: treatment-as-usual controls
No drinks are taken.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Externalizing and internalizing behavior problems
Time Frame: up to 12 months after initiation of trial: assessement at 0 months, 6 months (end of treatment) and 12 months (6 months post-tretament)
|
The following instruments will be administered to both caregivers and the children to assess child behavior behavior problems (externalizing and internalizing) Adolescent self-reported measures include Reactive-Proactive Aggression Questionnaire (RPQ), Antisocial Personality Screening Device (APSD), Conduct and Oppositional Defiant Disorder Questionnaire (COD) and Child Behavior Checklist (CBCL - Attention and Anxiety/Depressed subscales only). |
up to 12 months after initiation of trial: assessement at 0 months, 6 months (end of treatment) and 12 months (6 months post-tretament)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurocognitive functioning
Time Frame: up to 12 months
|
Neurocognitive functioning is assessed by the Tower of London.
The Tower of London is an assessment tool to examine the functional anatomy of planning.
It assesses high-order problem solving, specifically, executive planning abilities.
|
up to 12 months
|
|
Psychophysiological functioning
Time Frame: up to 12 months
|
Psychophysiological (attentional) functioning is assessed using EEG (P300 oddball task).
|
up to 12 months
|
|
Emotional empathy
Time Frame: up to 12 months
|
measured by a 10-items self-report instrument (CASES)
|
up to 12 months
|
|
Grit
Time Frame: up to 12 months
|
measured by an 8-item self-report instruments (GRIT)
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Annis Fung, Ph.D., City University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRF-11402514
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aggression
-
Boston UniversityU.S. Department of JusticeCompletedSexual Aggression | Offensive Aggression | Dating Violence Perpetration and VictimizationUnited States
-
University of KonstanzCompletedAppetitive AggressionGermany
-
New York State Psychiatric InstituteCompletedIrritable AggressionUnited States
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive AggressionUnited States
-
Weill Medical College of Cornell UniversityGreen Chimneys Residential Treatment Center, Brewster, NYCompletedChildhood AggressionUnited States
-
University of WashingtonNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Arizona State UniversityCompletedHeavy Drinking | Sexual AggressionUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive Aggression Comorbid With ADHDUnited Kingdom
-
Arizona State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Georgia State UniversityCompletedAlcohol Drinking | Sexual Behavior | Emotions | Sexual AggressionUnited States
-
Yale UniversityCompletedAnger | Irritable Mood | Disruptive Behavior | Aggression Childhood | Non-Compliance, PatientUnited States
Clinical Trials on Omega-3 supplemented drink
-
Centre for Chronic Disease Control, IndiaCompleted
-
Wageningen UniversityRecruiting
-
Fundación del Caribe para la Investigación BiomédicaNaturmegaNot yet recruitingMixed DyslipidemiaColombia
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Pennington Biomedical Research CenterCompleted
-
AstraZenecaCompletedDiabetes Mellitus, Type 2 | Exocrine Pancreatic InsufficiencySweden, Poland, Latvia, Denmark, Hungary, Slovakia
-
Appalachian State UniversityCompleted
-
Seoul National University HospitalUnknown
-
Fujian Medical UniversityEnrolling by invitationGraft-Versus-Host Disease(GVHD)China
-
Aarhus University HospitalCompletedHeart Failure With Reduced Ejection FractionDenmark